Home › Hearing Loss › Maryland
Hearing Loss clinical trials in Maryland
8 studies for Hearing Loss are looking for participants at sites in Maryland.
Cities in Maryland
Prevention of Ototoxicity in NTM Patients Treated With IV Amikacin
- Johns Hopkins University, Baltimore
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Oct 1, 2026 · NCT05730283NIDCD Otolaryngology Clinical Protocol Biospecimen Bank
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 3 to 99 · All sexes · Updated Sep 28, 2026 · NCT06303180Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
- University of Maryland Medical Center, Baltimore
- National Institutes of Health Clinical Center, Bethesda
RecruitingPhase 2
Ages 18 to 100 · All sexes · Updated Sep 2, 2026 · NCT04915183Open-label Study of SKY-GJB2 in Pediatric Subjects With GJB2-mediated Hearing Loss
- National Institutes of Health-Clinical Center, Bethesda
RecruitingPhase 1/2
9 Months – 7 Years · All sexes · Updated Aug 27, 2026 · NCT07627971Collection of Clinical Data and Specimens for Research in Hearing, Balance, Taste, Smell, Voice, Speech, and Language Disorders.
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational study
Ages 2 to 99 · All sexes · Updated Aug 18, 2026 · NCT05670496Natural History of Autosomal Dominant Hearing Loss
- National Institutes of Health Clinical Center, Bethesda
RecruitingObservational studyHealthy volunteers welcome
Ages 3 to 99 · All sexes · Updated Jul 23, 2026 · NCT04501081Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma
- Johns Hopkins Hospital, Baltimore
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Apr 6, 2026 · NCT06517888HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms
- Johns Hopkins Memory and Alzheimer's Treatment Center, Baltimore
RecruitingHealthy volunteers welcome
Ages 60 to 100 · All sexes · Updated Nov 24, 2025 · NCT06930560From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.